IMT, a subtype of IPT, have been found to harbor ALK gene rearrangements, which are thought to drive abnormal cellular proliferation and have led to the development and application of targeted therapies, such as ALK inhibitors, for specific IPT cases. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.